



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Itepekimab

Cat. No.:	HY-P99673
CAS No.:	2226742-52-3
Target:	Interleukin Related; NF-κB
Pathway:	Immunology/Inflammation; NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) <sup>[1][2][3][4]</sup> .
<b>In Vitro</b>	Itepekimab can bind IL-33 with high affinity and prevent the binding of ST2 D3 domain to IL-33, thus preventing the formation of IL-33/ST2/IL-1RAcP signaling complex and blocking the production of airway inflammatory mediator <sup>[4]</sup> . Itepekimab also binds with subnanomolar affinity to different IL-33 cleavage variants, blocks NF-κB signaling in reporter cell lines, and prevents cytokine release from human peripheral blood mononuclear cell <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Itepekimab ameliorates type 1 and type 2 lung inflammation and prevents characteristic lung remodeling in mice. Itepekimab prevents IL-33/ST2/IL-1RAcP complex formation and reconstitutes ciliated cells in a mouse model of persistent airway inflammation <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Wechsler ME, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. *N Engl J Med*. 2021 Oct 28;385(18):1656-1668.
- [2]. Kosloski MP, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. *Clin Transl Sci*. 2022 Feb;15(2):384-395.
- [3]. Rabe KF, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. *Lancet Respir Med*. 2021 Nov;9(11):1288-1298.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA